Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,otherCurrentAssets,intangibleAssets,longTermInvestments,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,investments,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,FSTX,19860000.0,19365900,7267000,,-9761000,,-9869000,6429000,2917000,-10779000,-10779000,,,,,,108000,2917000,13696000,0,1018000,,-9869000,-9869000,93418000.0,18596000.0,34840000.0,19157000.0,2200000.0,53436000.0,1000.0,-57037000.0,896000.0,14980000.0,-1542000.0,19611000.0,3680000.0,14315000.0,-1542000.0,5041000.0,13804000.0,6816000.0,4084000.0,,,,-852000.0,-252000.0,-2439000.0,-14846000.0,-216000.0,-14378000.0,144000.0,-2805000.0,1856000.0,-267000.0,,,,,,,-511000.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,6.739,6.9402676,0.971 - 15.5,-7.79,-0.50258064,0.971,15.5,1606089600,1617008400,1635764340,1636113600,-3.06,-2.6515155,7.6497 - 8.1099,7.92,7.51,8.1,9,10,finmb_662294213,NasdaqCM,"F-star Therapeutics, Inc.",USD,161910,98433,-2.519608,6.2243056,1.4856944,0.23869239,8.21808,-0.5080795,-0.061824605,149311088,15,America/New_York,EDT,-14400000,2,NCM,POST,us_market,"F-star Therapeutics, Inc.",7.71,1630526403,-0.21000004,8.01,8.1099,7.6497,55800,,,,15.5,0.97,6.22,8.22,161.91k,98.43k,19.37M,,12.48M,1.33%,38.84%,105.4k,0.39,0.55%,0.54%,37.71k,,,,,,0.00%,"Nov 22, 2020",,,,"Dec 30, 2020","Mar 30, 2021",-221.01%,-185.13%,-25.73%,-130.62%,12.82M,1.41,115.30%,11.26M,-22.62M,-28.33M,,,3.68M,0.19,4.35M,12.50,0.96,,-29.08M,,Value,CB22 3AT,Healthcare,75,"F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 1223 497 400,1609372800,United Kingdom,http://www.f-star.com,86400,Eddeva B920,Biotechnology,Babraham Research Campus
t-1,FSTX,28068000.0,19365900,1997005,,-3234079,,-5070968,4270348,4805656,-1461697,-1461697,,-5659.0,,,,1836889,4578467,6040164,-227189,-1772382,,-5070968,-5743113,91238000.0,20615000.0,42994000.0,18986000.0,2380000.0,63609000.0,1000.0,-47168000.0,1016000.0,14926000.0,-1077000.0,19047000.0,18526000.0,16977000.0,-1077000.0,3571000.0,26065000.0,4426000.0,4597000.0,2131000.0,,,-991786.0,7018841.0,-1460500.0,7891857.0,78.0,-6933207.0,-278889.0,-473257.0,-2129807.0,-267000.0,2500000.0,299397.0,7806145.0,7500000.0,-5659.0,6748.0,9088000.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,6.739,6.9402676,0.971 - 15.5,-7.79,-0.50258064,0.971,15.5,1606089600,1617008400,1635764340,1636113600,-3.06,-2.6515155,7.6497 - 8.1099,7.92,7.51,8.1,9,10,finmb_662294213,NasdaqCM,"F-star Therapeutics, Inc.",USD,161910,98433,-2.519608,6.2243056,1.4856944,0.23869239,8.21808,-0.5080795,-0.061824605,149311088,15,America/New_York,EDT,-14400000,2,NCM,POST,us_market,"F-star Therapeutics, Inc.",7.71,1630526403,-0.21000004,8.01,8.1099,7.6497,55800,,,,15.5,0.97,6.22,8.22,161.91k,98.43k,19.37M,,12.48M,1.33%,38.84%,105.4k,0.39,0.55%,0.54%,37.71k,,,,,,0.00%,"Nov 22, 2020",,,,"Dec 30, 2020","Mar 30, 2021",-221.01%,-185.13%,-25.73%,-130.62%,12.82M,1.41,115.30%,11.26M,-22.62M,-28.33M,,,3.68M,0.19,4.35M,12.50,0.96,,-29.08M,,Value,CB22 3AT,Healthcare,75,"F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 1223 497 400,1609372800,United Kingdom,http://www.f-star.com,86400,Eddeva B920,Biotechnology,Babraham Research Campus
t-2,FSTX,28068000.0,19365900,2264738,,-3740056,,-5479860,4449267,4849107,-1864898,-1864898,,-5360.0,,,,1739804,4633923,6498820,-215184,-1875159,,-5479860,-6116490,91238000.0,20615000.0,42994000.0,18986000.0,2380000.0,63609000.0,1000.0,-47168000.0,1016000.0,14926000.0,-1077000.0,19047000.0,18526000.0,16977000.0,-1077000.0,3571000.0,26065000.0,4426000.0,4597000.0,2131000.0,,,-1018534.0,7019140.0,-1460500.0,7834825.0,-1194.0,-6995546.0,-233929.0,-448251.0,-1826472.0,-267000.0,2500000.0,306034.0,7812425.0,7500000.0,-5360.0,6391.0,9088000.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,6.739,6.9402676,0.971 - 15.5,-7.79,-0.50258064,0.971,15.5,1606089600,1617008400,1635764340,1636113600,-3.06,-2.6515155,7.6497 - 8.1099,7.92,7.51,8.1,9,10,finmb_662294213,NasdaqCM,"F-star Therapeutics, Inc.",USD,161910,98433,-2.519608,6.2243056,1.4856944,0.23869239,8.21808,-0.5080795,-0.061824605,149311088,15,America/New_York,EDT,-14400000,2,NCM,POST,us_market,"F-star Therapeutics, Inc.",7.71,1630526403,-0.21000004,8.01,8.1099,7.6497,55800,,,,15.5,0.97,6.22,8.22,161.91k,98.43k,19.37M,,12.48M,1.33%,38.84%,105.4k,0.39,0.55%,0.54%,37.71k,,,,,,0.00%,"Nov 22, 2020",,,,"Dec 30, 2020","Mar 30, 2021",-221.01%,-185.13%,-25.73%,-130.62%,12.82M,1.41,115.30%,11.26M,-22.62M,-28.33M,,,3.68M,0.19,4.35M,12.50,0.96,,-29.08M,,Value,CB22 3AT,Healthcare,75,"F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 1223 497 400,1609372800,United Kingdom,http://www.f-star.com,86400,Eddeva B920,Biotechnology,Babraham Research Campus
t-3,FSTX,4216000.0,19365900,3400000,,-7147000,,-7159000,3189000,1355000,-5234000,-5234000,,-218774.0,,,,12000,1355000,6589000,166402,-2127629,,-7159000,-7159000,,26260454.0,8536000.0,,416739.0,44882404.0,178109.0,-26817953.0,1297333.0,2811827.0,45261794.0,,2155101.0,24963121.0,45261794.0,1032930.0,7623053.0,5467952.0,9898729.0,,33368882.0,45712.0,1865000.0,-62000.0,-199000.0,-1353000.0,-267000.0,-1524000.0,180000.0,346633.0,2605000.0,-267000.0,2500000.0,500000.0,500000.0,7500000.0,4145.0,-4943.0,-17340068.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,6.739,6.9402676,0.971 - 15.5,-7.79,-0.50258064,0.971,15.5,1606089600,1617008400,1635764340,1636113600,-3.06,-2.6515155,7.6497 - 8.1099,7.92,7.51,8.1,9,10,finmb_662294213,NasdaqCM,"F-star Therapeutics, Inc.",USD,161910,98433,-2.519608,6.2243056,1.4856944,0.23869239,8.21808,-0.5080795,-0.061824605,149311088,15,America/New_York,EDT,-14400000,2,NCM,POST,us_market,"F-star Therapeutics, Inc.",7.71,1630526403,-0.21000004,8.01,8.1099,7.6497,55800,,,,15.5,0.97,6.22,8.22,161.91k,98.43k,19.37M,,12.48M,1.33%,38.84%,105.4k,0.39,0.55%,0.54%,37.71k,,,,,,0.00%,"Nov 22, 2020",,,,"Dec 30, 2020","Mar 30, 2021",-221.01%,-185.13%,-25.73%,-130.62%,12.82M,1.41,115.30%,11.26M,-22.62M,-28.33M,,,3.68M,0.19,4.35M,12.50,0.96,,-29.08M,,Value,CB22 3AT,Healthcare,75,"F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 1223 497 400,1609372800,United Kingdom,http://www.f-star.com,86400,Eddeva B920,Biotechnology,Babraham Research Campus
